Citations

Clear

384 citation(s) found for "Hoffman, O A".

Impact of cytoreductive therapy in myeloproliferative neoplasm-associated splanchnic vein thrombosis
Ko, A.K. , Chrysafi, Pavlina , Zon, Rebecca L., Houghton, Damon E. , Ghorbanzadeh, Atefeh , Sastow, Dahniel, Alladi, Sai Swetha, Georgen, Maria, Prabhu, Abishta, Pachpande, Vrushali , Valisekka, Sai Sudha , Jahagirdar, Balkrishna, Peseski, Andrew M. , Gangaraju, Radhika , Zheng, Guoliang , Bhagirath, Vinai Chander, Godoy, Alejandro , Boldrini, Valentina , Betti, Silvia, Rossi, Elena, Berry, Jonathan , Maffioli, Margherita , Nayak, Amiya Ranjan , Dhawan, Rishi, Chiasakul, Thita , Lauw, Mandy N. , Tremblay, Douglas , Ko, Amica Kurniati , Chrysafi, Pavlina , How, Joan , Houghton, Damon E , Ghorbanzadeh, Atefeh , Pachpande, Vrushali , Kapoor, Sargam , Peseski, Andrew , Desai, Ruchi , Dalmia, Shreyash , Godoy, Alejandro Daniel , Iurlo, Alessandra , Cattaneo, Daniele , Vannucchi, Alessandro M , Boldrini, Valentina , De Stefano, Valerio , Ageno, Walter , Berry, Jonathan , Maffioli, Margherita , Aggarwal, Mukul , Chiasakul, Thita , Sanfilippo, Kristen , Hobbs, Gabriela S , Mascarenhas, John , Baumann Kreuziger, Lisa , Patell, Rushad D , Beckman, Joan D , Lauw, Mandy N , Zon, Rebecca L. , Sastow, Dahniel L. , Georgen, Maria R. , Bhagirath, Vinai C. , Guglielmelli, Paola , Vannucchi, Alessandro M. , Stefano, Valerio De , Betti, Silvia, Rossi, Elena, Ageno, Walter , Dhawan, Rishi , Hobbs, Gabriela , Mascarenhas, John , Hoffman, Ronald , Kreuziger, Lisa Baumann , Beckman, Joan D.

Mayo Clinic

Blood Advances | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020925 | PMID 42623680 Get It

Myeloproliferative neoplasm (MPN) patients are at risk of splanchnic vein thromboses (SVT). Prior studies have failed to demonstrate a benefit of hydroxyurea therapy in preventing recurrent thrombosis after SVT, but are limited by small sample sizes and inability to account for starting, stopping, or switching of cytoreductive therapies. To better assess the impact of cytoreductive therapy on thrombosis recurrence, we performed a retrospective cohort study of MPN-SVT patients from the international GASTRO-MPN Consortium, treating cytoreductive therapy as a time-dependent covariate. We identified 757 patients, of which 43% were treated with cytoreductive therapy. During a median follow-up of 7.4 years, 256 patients (34%) had thrombosis recurrence; 145 (19%) had SVT extension/recurrence/TIPS thrombosis, 138 (18%) an thrombosis recurrence outside the splanchnic bed (74% were venous). Additionally, 262 patients (35%) experienced clinically relevant bleeding and 170 (22%) died. After adjusting for age, sex, prior thrombosis, timing of MPN diagnosis relative to SVT, anticoagulation initiation within 30 days of SVT diagnosis, MPN type, JAK2 status, other cancers and cirrhosis, cytoreductive therapy was associated with a decreased risk of recurrent thrombosis (HR 0.67 95%CI 0.50-0.89, p=0.01). This was driven by a lower risk of SVT extension/recurrence (HR 0.62 95%CI 0.42-0.90, p=0.01) but not by extra-splanchnic thrombosis recurrence (HR 0.97 95%CI 0.72-1.30, p=0.82). In a subgroup of patients without erythrocytosis/thrombocytosis at initial SVT (n=275), cytoreductive therapy was associated with a HR 0.65 (95%CI 0.40-1.07, p=0.09) for recurrent thrombosis. These data support the use of cytoreductive therapy in MPN-SVT patients to prevent recurrent thrombosis, particularly SVT extension/recurrence.
Enrichment of methylated cell-free placental DNA
Smith, Keaton W , Yuen, Natalie , Shen, Shu Yi , Girard, Sylvie , Cheng, Nicholas , Awadalla, Philip , Triche, Timothy J. , Tuzhilina, Elena , Sylvie, Girard , Yuen, Natalie , Bratman, Scott V , Carvalho, Daniel Diniz De , Wilson, Samantha L. , Hoffman, Michael M.

Mayo Clinic

No container title available | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.17.745276 Get It

Abstract. Introduction: Preterm birth drives adverse perinatal maternal and infant health outcomes through heterogeneous symptoms, severity, and etiologies. Delivery prior to reaching 37 weeks of gestation may result from medically indicated intervention for pregnancy complications or spontaneously in the absence of prior symptoms. Placental tissue collected following preterm birth exhibits differential DNA methylation compared to full-term placentas and may indicate pregnancy health during gestation. Placental DNA currently has limited utility for assessing health of ongoing pregnancy, as sampling placental tissue during gestation increases the risk of infection and miscarriage. Risks associated with placental sampling during pregnancy limit the use of DNA methylation in clinical preterm birth prediction. Assessing preterm birth risk during gestation requires non-invasive methods for characterizing placental DNA methylation. Results: We quantified genome-wide DNA methylation patterns of hypermethylated cell-free DNA in pregnant (n = 99) and non-pregnant (n = 93) plasma using cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq). In each sample, we assessed DNA methylation status in 300-bp genomic windows, examining both sequencing read counts and calculated absolute molar DNA amount. Known hypermethylated placental regions, including RASSF1, STAT5A, and ERG promoters showed significantly increased odds of detection in pregnant samples, suggesting enrichment of cell-free placental DNA. Of the 536,444 300-bp windows examined, 173,071 (32%) showed significant enrichment in pregnant plasma. Linear modeling identified 107,505 differentially methylated regions (DMRs) associated with pregnancies later diagnosed with intrauterine growth restriction (IUGR) (n = 22). Alu elements showed increased representation in these DMRs than expected, while other repetitive elements exhibited underrepresentation. Discussion: These results demonstrate cfMeDIP-seq's ability to enrich for cell-free placental DNA and characterize cell-free DNA methylation signatures of pregnancies complicated by IUGR. Enrichment of cell-free placental DNA enables non-invasive profiling of placental DNA methylation from maternal plasma. Detectable epigenetic signatures in maternal plasma may identify pregnancies at elevated risk for preterm birth before clinical symptoms appear. Our findings further highlight the potential of cell-free placental DNA for monitoring pregnancy health.
Sapablursen for erythrocytosis control in patients with polycythemia vera
Palmer, Jeanne , How, Jonathan, Bose, Prithviraj , Vachhani, Pankit , Mead, Adam J. , Sillar, Jonathan, Gerds, Aaron T. , Fleischman, Angela G. , O’Neill, Caitlin , Baker, Ross , Hoffman, Ronald, Jung, Shiangtung, Ruckle, Jon, Bhanot, Sanjay , Barrett, Terrance D. , Palmer, Jeanne M , O'Neill, Caitlin M , Baker, Ross Ian , Barrett, Terrance D , Gerds, Aaron T , Mead, Adam J , Fleischman, Angela G , Bose, Prithviraj , Sillar, Jonathan R. , Hoffman, Ronald , Yousefi, Keyvan , Mesa, Ruben A.

Mayo Clinic

Blood | August 18, 2026 | Volume: 148 | Issue: 20 | Pages: 2477-2488

10.1182/blood.2026033792 | PMID 42611791 Get It

Abstract Polycythemia vera is characterized by erythrocytosis and an increased risk of thrombosis. Sapablursen is an antisense oligonucleotide that suppresses transmembrane serine protease 6, increases hepcidin production, and reduces iron availability for erythropoiesis. IMPRSSION is an ongoing phase 2a, randomized, open-label study in patients with phlebotomy-dependent polycythemia vera. Cohort A (120 or 80 mg) and cohort B (40 mg) received sapablursen subcutaneously once every 4 weeks. The primary efficacy end point was the reduction in phlebotomy frequency from baseline to weeks 17 to 37 in patients who received ≥1 dose. The baseline mean ± standard deviation weekly phlebotomy rate was 0.15 ± 0.07 in cohort A and 0.17 ± 0.07 in cohort B, with reduction by −0.10 (95% confidence interval [CI], −0.13 to −0.07; n = 32; P< .0001) in cohort A and by −0.10 (95% CI, −0.14 to −0.06; n = 17; P = .0001) in cohort B. Sapablursen reduced the median number of phlebotomies from 5.0 at baseline (26 weeks) to 0 in cohort A and 1.5 in cohort B in the efficacy evaluation window (20 weeks). Most adverse events were mild or moderate; anemia and fatigue were most common. The mean change in the myeloproliferative neoplasm–symptom assessment form total symptom score at week 37 was −6.21 points (95% CI, −10.56 to −1.85; P = .0052) in cohort A and −2.71 points in cohort B (95% CI, −8.33 to 2.91; P = .34). Sapablursen reduced phlebotomy need, improved symptoms, and was safe and well tolerated in patients with polycythemia vera. This trial was registered at www.clinicaltrials.gov as NCT05143957.
Standardization of postoperative adverse event reporting: A critical opportunity for improvement within the National Clinical Trials Network
Helmink, Beth, Raut, Chandrajit P. , Mandrekar, Sumithra J. , Laumann, Kristina, Booth, Allison, Hoffman, Laura , Singer, Eric A. , Bedrosian, Isabelle , Snyder, Rebecca A. , Katz, Matthew H G , Bedrosian, Isabelle , Snyder, Rebecca A , Katz, Matthew H. G. , Laumann, Kristina

Mayo Clinic

Cancer | July 28, 2026 | Volume: 132 | Issue: 15 | Pages: No page available

10.1002/cncr.70555 | PMID 42516051 Get It

Although structured reporting of adverse events related to medical therapies is a critical aspect of clinical trials, the current practice fails to capture postoperative complications accurately or systematically, which precludes our ability to fully assess the impact of the risks of surgical interventions on oncologic outcomes. The incorporation of standardized, procedure‐specific definitions and severity classifications for postoperative complications into adverse event reporting in trials conducted through the National Clinical Trials Network is proposed.
Impact of Cardiomyopathy and Arrhythmia Genetic Testing on Clinical Management Decisions
Morales, Ana , Ting, Yi‐Lee , Bucknor, Brianna, Chahal, C. Anwar A. , Judge, Daniel P. , Owens, Anjali , Wang, Jessica , Alkhayat, Mohamad, Barker, Naomi, Betts, Megan , Chowns, Jessica, Eberly, Rebecca M, Hoffman‐Andrews, Lily , Koduri, Ajit, Padmanabhan, Arun , Wojciak, Julianne , Higgs, Emily , Judge, Daniel P , Owens, Anjali T , Wang, Jessica , Alkhayat, Mohamad , Barker, Naomi , Betts, Megan , Esplin, Edward D , Hoffman-Andrews, Lily , Nair, Ajith P , Padmanabhan, Arun , Vedantham, Vasanth , Wojciak, Julianne , McNally, Elizabeth M , Chahal, Choudhary Anwar A , Morales, Ana , Bucknor, Brianna A., Chowns, Jessica L., Eberly, Rebecca, Higgs, Emily , Huth, Emily A. , Koduri, Ajit , Nair, Ajith, Esplin, Edward D. , McNally, Elizabeth M.

Mayo Clinic

No container title available | July 27, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.22.26358740 | PMID 42619823 Get It

ABSTRACT Background Genetic testing for cardiomyopathy and arrhythmia (CM/ARRH) provides diagnostic information and informs screening for at-risk relatives. Clinical guidelines recommend genetic testing for these conditions; however, data on how genetic test results influence clinical management recommendations are limited. Here, we determined the frequency of cardiologist-recommended management changes for patients following CM/ARRH genetic testing. Methods This was a retrospective cross-sectional study of patients referred for multigene panel testing between April 2016 and April 2024. Genetically-experienced cardiologists at multicenter academic clinical practices were recruited for participation to complete surveys indicating clinical decision making on patients who had genetic testing. Cases for review were randomly selected to have both positive and non-positive results. Results Among 249 patients (138 positive, 111 non-positive), 136 (54.6%) received clinical management recommendations for their own or their at-risk relatives’ care. Of these, 75 (55.1%) received recommendations for the patient’s own care, most frequently additional diagnostic tests/procedures (n=33). Compared to non-positive results, patients with positive results were more likely to receive recommendations for their own management (66/138, 47.8% vs 9/111, 8.1%; P<0.00001). Patients with positive results in arrhythmogenic cardiomyopathy genes had 263% higher odds of recommended management changes compared to those with TTN (OR=3.63, CI:1.40-9.84, P=0.009). Conclusions The results from CM/ARRH genetic testing on affected patients influenced cardiologists’ medical decision making and management recommendations. Additional research is needed to evaluate how genetic testing for CM/ARRH impact health outcomes.
Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy
Tersalvi, Gregorio , Bois, Melanie C. , Scott, Christopher G. , Carey, Patricia , Garmany, Armin , Davies, Daniel R. , HOFFMAN, Andrew C., Zhang, Jun , Hruska, Carrie B. , Jouni, Hayan, Rodriguez-Porcel, Martin G., Askew, J. Wells , Bois, John P. , Young, Kathleen A. , Anavekar, Nandan S., CHANG, IAN C., Grogan, Martha , Maleszewski, Joseph J. , Homb, Andrew, Redfield, Margaret M. , Dispenzieri, Angela , Maleszewski, Joseph J , Homb, Andrew C, Redfield, Margaret M , Chareonthaitawee, Panithaya , Johnson, Geoffrey B , AbouEzzeddine, Omar F , Hruska, Carrie B , Scott, Christopher , Tersalvi, Gregorio , Carey, Patricia , Rodriguez‐Porcel, Martin , Anavekar, Nandan S., Dispenzieri, Angela , Chareonthaitawee, Panithaya , Johnson, Geoffrey B. , AbouEzzeddine, Omar F.

Mayo Clinic

Circulation: Cardiovascular Imaging | July 23, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1161/circimaging.126.019832 | PMID 42488949 Get It

BACKGROUND: Technetium-based cardiac amyloid radionuclide imaging enables noninvasive diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM), but conventional planar and visual semiquantitative approaches have important limitations. We developed the quantitative 3-dimensional Mayo 3D Score, defined as the ratio of mean left ventricular myocardial radiotracer uptake to right atrial blood-pool uptake using computed tomography (CT)-fused single-photon emission CT (SPECT) volumes of interest, and sought to validate its diagnostic performance against myocardial pathology. METHODS: Consecutive patients who underwent 99m Tc-pyrophosphate SPECT/CT at Mayo Clinic for suspected ATTR-CM between June 2017 and January 2025 with archived myocardial tissue were included. Baseline characteristics, including demographics, echocardiogram, biomarkers, visual semiquantitative, and Mayo 3D Score metrics, were collected. Myocardial specimens underwent histopathologic confirmation of amyloid, with amyloid subtype determination and further semiquantitative grading of amyloid burden and deposition patterns. RESULTS: Among 230 patients (median age, 72 years; 78% male), 107 (47%) had ATTR-CM, of whom 9 had hereditary ATTR-CM. The Mayo 3D Score showed excellent discrimination against pathology (area under the receiver operating characteristic curve, 0.92 [0.88–0.96]), exceeding planar Perugini (0.87 [0.83–0.92]; P =0.006), and heart-to-contralateral lung ratio (0.86 [0.81–0.91]; P =0.004) and comparable to SPECT Perugini (0.90 [0.86–0.94]; P =0.12). A cutoff ≥1.0 yielded 86.0% sensitivity, 92.7% specificity, 91.1% positive predictive value, and 88.4% negative predictive value. Among ATTR-positive cases, the Mayo 3D Score correlated strongly with semiquantitative amyloid burden (Spearman ρ=0.69), was higher in pericellular than nodular deposition patterns ( P <0.001), and was not associated with vascular involvement ( P =0.42). CONCLUSIONS: In patients with suspected ATTR-CM undergoing 99m Tc-pyrophosphate SPECT/CT, the Mayo 3D Score demonstrated superior diagnostic performance compared with planar metrics and comparable to SPECT Perugini, while correlating with myocardial ATTR burden and deposition patterns on pathology. These findings support its integration as a quantitative adjunct within clinical diagnostic ATTR-CM workflows.
Low-frequency bipolar versus high-frequency monopolar cortical and subcortical motor mapping in craniotomies for brain tumors
Chow, William, Loron, Ali Gharibi , Keough, Michael B. , Malik, Noor, You, Hyo Bin , Do, B., Schwartz, J, Reilly, Charles, Michaelcheck, Charlotte E., Hoffman, Ernest M., Chow, William D, Do, Bobby, Schwartz, Jenna , Bauman, Megan M. J. , Parney, Ian F.

Mayo Clinic

Journal of Neurosurgery | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-10

10.3171/2026.1.jns251897 | PMID 42430806 Get It

OBJECTIVE Maximal safe resection of intra-axial brain tumors near the motor cortex is aided by intraoperative motor mapping. Here, the authors compared outcomes in patients undergoing either low-frequency bipolar stimulation (LFBS) or high-frequency monopolar stimulation (HFMS) for cortical and/or subcortical motor mapping during brain tumor resection. METHODS A retrospective analysis of patients undergoing an asleep craniotomy with motor mapping or an awake craniotomy with motor and speech mapping with a single surgeon was performed. Three cohorts were compared: 1) asleep LFBS (AsLFBS), 2) awake LFBS (AwLFBS; motor + speech mapping), and 3) asleep HFMS. HFMS mapping was not used for awake craniotomies. RESULTS A total of 284 patients who underwent 300 craniotomies with motor mapping were identified. No significant differences in permanent neurological deficits (p = 0.377) or extent of resection (EOR) of nonenhancing tumors (p = 0.453) were identified between LFBS or HFMS motor mapping cases. Both EOR (92.7% vs 83.5%, p = 0.035) and permanent neurological deficits (7.6% vs 3.3%) occurred more frequently in enhancing tumors with LFBS, although the latter was not statistically significant. HFMS was associated with higher rates of subcortical motor pathway identification (p = 0.001) and fewer total intraoperative seizures (p = 0.003) compared with LFBS. Previous resection (HR 0.46, p = 0.003) and a higher cortical threshold (HR 0.95, p = 0.023) were significantly associated with longer survival, while preoperative aphasia (HR 2.24, p = 0.022), hospital length of stay (HR 1.1, p = 0.005), an insular-based tumor (HR 3.5, p = 0.021), and a histological diagnosis of glioblastoma (HR 2.9, p = 0.001) were negative predictors. Interestingly, overall FLAIR EOR was significantly associated with a marginally decreased overall survival (HR 1.01, p = 0.011). CONCLUSIONS No significant differences in postoperative neurological deficits were found between LFBS and HFMS paradigms. HFMS may identify subcortical motor fibers more reliably while resulting in significantly fewer intraoperative seizures. Although LFBS was associated with greater EOR of contrast-enhancing tumors, it may also be associated with higher rates of postoperative deficits, perhaps reflecting less reliable identification of subcortical motor fibers.
A75-04 Covid-19 and Changes in Lung Health in a General Population-based Cohort: The Mesa Lung Study
Balte, P, Sun, Y, Kim, J, Allen, N, Bowler, R P, Regan, E A, Hoffman, E A, Lynch, D A, O’Connor, G T, Post, W, Smith, B M, Woodruff, P, Ortega, V E, Barr, R G, Oelsner, E, Balte, Pallavi , Kim, J, Bowler, R P, Regan, E.A., Hoffman, E A, Lynch, David A. , O’Connor, G T, Smith, B.M. , Woodruff, P., Oelsner, E

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.118 Get It

Abstract Rationale Impaired lung health may serve as a risk factor for, and a post-acute sequela of, SARS-CoV-2 infection. Yet most prior studies of lung health sequelae of COVID-19 lacked information on pre-infection lung health, a major antecedent confounder. To identify associations of COVID-19 with changes in lung health, we leveraged paired pre- and post-pandemic data on respiratory symptoms, lung function, and lung structure in a general population-based cohort. Methods We studied participants in the Multi-Ethnic Study of Atherosclerosis Lung Study with paired pre-pandemic (2016-2018) and post-pandemic (2022-2024) assessments of respiratory symptoms, spirometry, and lung CT. SARS-CoV-2 infection (2020-2023) was ascertained using a composite of questionnaires, serology, and medical record adjudication, and classified as severe (requiring hospitalization) or non-severe (not requiring hospitalization). Lung health was assessed by questionnaire (mMRC grade ≥2 dyspnea, chronic cough, chronic phlegm, chronic bronchitis), pre-bronchodilator spirometry (FEV1, FVC, FEV1:FVC), and lung density on non-contrast lung CT (% low attenuation areas, % high attenuation areas). Each post-pandemic lung health measure was regressed on infection history and the corresponding pre-pandemic lung health measure, adjusting for age at post-pandemic exam, sex, race/ethnicity, smoking status, and vaccination status at infection. Sensitivity analyses were included- (a) restriction to participants without pre-pandemic respiratory symptoms and (b) with additional adjustment for time since infection and variant wave. Results Among 2,015 participants (mean age 77.2±7.5 years; 55% female; 40% non-Hispanic White; 25% Black; 11% Asian; 23% Hispanic/Latino), 59 (3%) experienced severe and 506 (25%) non-severe SARS-CoV-2 infection. The prevalence of respiratory symptoms was similar or slightly higher at the post- vs. pre-pandemic exam (grade ≥2 dyspnea: 14% vs. 10%; chronic cough: 10% vs. 8%; chronic phlegm: 9% vs. 8%; chronic bronchitis: 4% vs. 4%; p-values &lt;0.0001). Compared with participants without infection, those with severe infection had higher odds of chronic cough (OR:2.9, 95%CI:1.3-6.3) and chronic bronchitis (OR:3.3, 95%CI:1.2-9.0) at the post-pandemic exam (Table). Associations were stronger among individuals infected &gt;90 days prior to the post-pandemic assessment and during pre-Omicron waves. Results were similar when restricted to participants without pre-pandemic symptoms. No significant associations were observed for non-severe infection (vs. no infection) or for any other lung health outcomes. Conclusions Controlling for pre-pandemic lung health, severe COVID-19 was associated with increased odds of chronic cough and chronic bronchitis but not with changes in lung function or structure in a general population-based sample. Non-severe COVID-19 was not associated with lung health outcomes. This abstract is funded by: OT2HL156812, R21HL165405, R01HL077612, 75N92025D00022, 75N92025D00026, 75N92020D00002, 75N92025D00024, 75N92025D00027, 75N92025D00025, 75N92025D00028
C101-09 Lower Airway-to-lung Ratio Links to Neutrophil/macrophage Inflammation and Impaired Mucociliary Clearance in Current Smokers in SPIROMICS
Kelly, M E, Woodruff, P G, Curtis, J L, Paine, R, Barjaktarevic, I, Hoffman, E A, Bleecker, E R, Meyers, D A, Bowler, R P, Barr, R G, Cooper, C B, Couper, D, Han, M K, Putcha, N, Kaner, R J, Hansel, N N, O’Neal, W K, Martinez, F J, Ortega, V E, Smith, B M, Christenson, S A, Investigators, SPIROMICS, Curtis, Jeffrey L. , Hoffman, Eric A. , Meyers, Deborah A. , Barr, R. Graham , Han, MeiLan King , Kaner, R.J. , Hansel, Nadia N. , O’Neal, Wanda K. , Christenson, S A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2028 Get It

Abstract Rationale Mismatch of airway to lung size has been implicated in chronic obstructive pulmonary disease (COPD) pathophysiology, whether arising from disproportioned growth or from acquired pathologies over the life course. Lower airway-to-lung ratio (ALR), assessed reproducibly via computed tomography (CT) as the mean airway lumen diameters (trachea-to-subsegments) divided by the cubed root of lung volume, is associated with COPD risk and mortality (all-cause, respiratory, cardiovascular, lung cancer). We sought to characterize the airway biology associated with lower ALR by profiling bronchial gene expression across current and former smokers. Methods We leveraged clinical, radiologic, and bronchial epithelial RNA sequencing data from the SPIROMICS (SubPopulations and Intermediate Outcomes Measures in COPD Study) Phase 1 Bronchoscopy Sub-study (n = 161). To analyze transcriptional differential expression (DE) between participants based on CT-assessed ALR, we utilized DESeq2 and then identified impacted pathways by Ingenuity Pathway Analysis (IPA). Generating cell-type transcriptional signatures from lung and blood single cell sequencing atlases, we also assessed association of ALR with differences in airway cellular composition. Results Across all ever-smokers, after adjustment for age, sex, height, COPD status, smoking status, and pack-years, n = 1,324 genes from airway epithelial samples exhibited DE at a false discovery rate (FDR) &lt;0.2. Per IPA, enriched pathways associated with lower ALR included neutrophilic degranulation and macrophage activity. In cell type analysis, lower ALR was associated with higher signatures of macrophages, neutrophils, dendritic cells, and B cells, and lower ciliated and club cell signatures. When we repeated DE analysis using the same covariate adjustments plus an interaction term for ALR and smoking, n = 713 DE genes were identified at FDR &lt;0.2; the association of DE with lower ALR was overwhelmingly in current rather than former smokers (3699 vs. 2 genes). By pathway and cell type analyses, the association between lower ALR and heightened inflammation (greater macrophage and neutrophil signaling) and epithelial dysregulation (downregulated ciliated and club cell function) was primarily restricted to current smokers. Conclusions In adult ever-smokers, lower ALR is associated with transcriptomic evidence of heightened neutrophil- and macrophage-driven airway inflammation and reduced ciliated and club cell expression, associations that were most evident among current smokers. Whether these cross-sectional patterns, which suggest impaired mucociliary defense and a diminished capacity to clear inhaled particulates, are the result of pre-existing reduced ALR, its cause, or both, will require further investigation. This abstract is funded by: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, 75N92024D00012), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, and R01HL093081), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Verona; and Mylan/Viatris.
C101-08 Discordant Airway Gene Expression of TSLP and Its Specific Receptor Subunit, CRLF2, Links CRLF2 to Mixed Granulocytic Inflammation and Lung Function Decline in SPIROMICS
Kelly, M E, Komori, K, Barjaktarevic, I, Curtis, J L, Bleecker, E R, Bowler, R P, Barr, R G, Comellas, A P, Cooper, C B, Couper, D, Han, M K, Hansel, N N, Hoffman, E A, Kaner, R J, Martinez, F J, Meyers, D A, O’Neal, W K, Ortega, V E, Paine, R, Smith, B M, Woodruff, P G, Christenson, S A, Investigators, SPIROMICS, Comellas, Alejandro P. , Comellas, Alejandro P , Curtis, Jeffrey L. , Barr, R. Graham , Han, MeiLan King , Hansel, Nadia N. , Hoffman, Eric A. , Kaner, R.J. , Meyers, Deborah A. , O’Neal, Wanda K. , Christenson, S A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2027 Get It

Abstract Rationale Thymic stromal lymphopoietin (TSLP) is an epithelial alarmin chiefly implicated in T2 airway inflammation, though it may also participate in broader (non-T2) inflammatory processes. The utility of airway epithelial gene expression of TSLP and its specific receptor subunit, cytokine receptor-like factor 2 (CRLF2), as biomarkers of downstream inflammation and clinical outcomes remains unclear. Methods We analyzed RNA sequencing data from bronchial airway brushing obtained in phase 1 of the SPIROMICS bronchoscopy sub-study (N = 161: 23 never-smokers, 67 ever-smokers with COPD, 71 ever-smokers without COPD). We related airway TSLP and CRLF2 expression to clinical, hematologic/sputum measures, and gene-expression signatures of T2/eosinophilic and neutrophilic inflammation, including to our published T2 signature and to eosinophil and neutrophil signatures derived from single-cell atlas data. Associations used Spearman correlations and linear models adjusted for age, sex, race/ethnicity, COPD status, smoking status, and pack-years. Results CRLF2 expression correlated with gene-expression evidence of both T2/eosinophilic and neutrophilic inflammation: T2 signature (ρ = 0.26, p &lt; 0.001), eosinophil signature (ρ = 0.44, p &lt; 0.001), and neutrophil signature (ρ = 0.39, p &lt; 0.001). CRLF2 was positively associated with log sputum neutrophil count (ρ = 0.24, p = 0.024) and blood neutrophil count (ρ = 0.036, p &lt; 0.001), but not with sputum or blood eosinophil counts. Higher CRLF2 related to worse baseline lung function, particularly among current smokers, (lower post-bronchodilator FEV1: ρ = −0.21, p = 0.008), as well as greater 5-year FEV1 decline across current and former smokers (ρ = −0.22, p = 0.007). Significant findings persisted after covariate adjustment. In contrast, TSLP expression, although strongly correlated with expression of the epithelial alarmin IL33 (ρ = 0.53, p &lt; 0.001), was negatively correlated with CRLF2 (ρ = −0.24, p = 0.002) and with eosinophil and neutrophil gene-expression signatures (ρ = −0.26 and −0.33, both p &lt; 0.001). TSLP expression showed no association with sputum or blood cell counts. Conclusions In bronchial epithelium from SPIROMICS, gene expression of CRLF2, but not of TSLP, tracked with downstream alarmin-relevant inflammatory programs, consistent with a regulatory role in TSLP signaling through TSLPR, as well as with clinically meaningful outcomes. CRLF2 expression was associated with evidence of both T2/eosinophilic and neutrophilic inflammation, and with lower baseline FEV1 and accelerated FEV1 decline, suggesting engagement of a broader, clinically relevant inflammatory milieu. By contrast, epithelial TSLP transcript levels mirrored IL33 gene expression but were not associated with cellular or transcriptomic inflammation. These findings position CRLF2, rather than TSLP expression itself, as a potential airway biomarker of TSLP-axis activity and disease impact with potential implications for patient stratification as well as strategic approaches for TSLP-pathway-targeted therapies. This abstract is funded by: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C, 75N92024D00012), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, and R01HL093081), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Verona; and Mylan/Viatris.